CY1117841T1 - Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-yδροξυκωδεϊνονη - Google Patents

Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-yδροξυκωδεϊνονη

Info

Publication number
CY1117841T1
CY1117841T1 CY20161100711T CY161100711T CY1117841T1 CY 1117841 T1 CY1117841 T1 CY 1117841T1 CY 20161100711 T CY20161100711 T CY 20161100711T CY 161100711 T CY161100711 T CY 161100711T CY 1117841 T1 CY1117841 T1 CY 1117841T1
Authority
CY
Cyprus
Prior art keywords
ppm
preparation
hydroxycodinone
oxoxide
hydrochlorine
Prior art date
Application number
CY20161100711T
Other languages
English (en)
Inventor
Robert Chapman
Lonn S Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117841(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1117841T1 publication Critical patent/CY1117841T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Σε ορισμένες ενσωματώσεις η εφεύρεση αναφέρεται σε μια διεργασία για την παρασκευή μιας σύνθεσης υδροχλωρικής οξυκωδόνης έχουσας λιγότερο από 25 ppm 14-υδροξυκωδεϊνόνη.
CY20161100711T 2004-03-30 2016-07-20 Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-yδροξυκωδεϊνονη CY1117841T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10
EP05730345.5A EP1730151B2 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Publications (1)

Publication Number Publication Date
CY1117841T1 true CY1117841T1 (el) 2017-05-17

Family

ID=35124996

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20111100503T CY1111487T1 (el) 2004-03-30 2011-05-23 Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
CY20151100357T CY1116327T1 (el) 2004-03-30 2015-04-17 Φαρμακευτικη δοσολογικη μορφη περιεχουσα υδροχλωρικη οξυκωδονη εχουσα λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
CY20161100188T CY1117228T1 (el) 2004-03-30 2016-03-04 Διεργασια για την παρασκευη συνθεσεων υδροχλωρικης οξυκωδονης που εχουν λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
CY20161100711T CY1117841T1 (el) 2004-03-30 2016-07-20 Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-yδροξυκωδεϊνονη
CY20181100298T CY1120171T1 (el) 2004-03-30 2018-03-12 Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20111100503T CY1111487T1 (el) 2004-03-30 2011-05-23 Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
CY20151100357T CY1116327T1 (el) 2004-03-30 2015-04-17 Φαρμακευτικη δοσολογικη μορφη περιεχουσα υδροχλωρικη οξυκωδονη εχουσα λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
CY20161100188T CY1117228T1 (el) 2004-03-30 2016-03-04 Διεργασια για την παρασκευη συνθεσεων υδροχλωρικης οξυκωδονης που εχουν λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20181100298T CY1120171T1 (el) 2004-03-30 2018-03-12 Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη

Country Status (38)

Country Link
US (35) US7129248B2 (el)
EP (7) EP2316837B1 (el)
JP (8) JP4912294B2 (el)
KR (12) KR20180088505A (el)
CN (5) CN102887903B (el)
AP (1) AP2232A (el)
AR (1) AR049012A1 (el)
AT (2) ATE501150T1 (el)
AU (2) AU2005230826C1 (el)
BR (1) BRPI0508758B8 (el)
CA (3) CA2557845C (el)
CR (2) CR8593A (el)
CY (5) CY1111487T1 (el)
DE (2) DE202005021371U1 (el)
DK (6) DK2426132T3 (el)
EA (1) EA013208B1 (el)
EC (1) ECSP066953A (el)
ES (6) ES2566363T3 (el)
FI (1) FI7843U1 (el)
HR (5) HRP20110425T4 (el)
HU (3) HUE029913T2 (el)
IL (8) IL178038A (el)
LT (2) LT2314589T (el)
MA (1) MA28492B1 (el)
ME (4) ME02482B (el)
MX (2) MX363228B (el)
MY (3) MY172063A (el)
NO (1) NO337669B1 (el)
NZ (3) NZ601326A (el)
PE (1) PE20050880A1 (el)
PL (5) PL2426132T3 (el)
PT (5) PT2316837T (el)
RS (5) RS54598B1 (el)
SG (3) SG10201406658VA (el)
SI (5) SI2426132T1 (el)
TW (3) TW201509943A (el)
WO (1) WO2005097801A1 (el)
ZA (1) ZA200607181B (el)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
JP4939217B2 (ja) * 2003-08-06 2012-05-23 グリューネンタ−ル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用防止剤形
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CA2598774C (en) * 2005-03-04 2010-12-21 Euro-Celtique S.A. Method of reducing alpha, beta unsaturated ketones in opioid compositions
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
MX2008006710A (es) * 2005-11-22 2008-12-16 Controlled Chemicals Inc Procedimientos para reducir niveles de aceptor de michael contaminantes en oxicodona y otras composiciones.
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
AU2007224221B2 (en) * 2006-03-02 2013-02-14 SpecGx LLC Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
EP2073636B1 (en) * 2006-10-17 2012-09-05 Penick Corporation Process for preparing oxymorphone
AU2007329451B2 (en) * 2006-12-04 2012-08-30 Noramco, Llc Process for reducing impurities in oxycodone base
JP2010511726A (ja) 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド １４−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2681740A1 (en) * 2007-03-23 2008-10-02 Mallinckrodt Inc. Improved preparation of oxymorphone from oripavine
JP5373764B2 (ja) * 2007-04-16 2013-12-18 マリンクロッド エルエルシー 触媒性水素転移反応を使用する新規なオピエート還元
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
US8377453B2 (en) * 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
MX2012000317A (es) * 2009-07-22 2012-02-08 Gruenenthal Gmbh Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
WO2011141488A2 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
NZ603173A (en) 2010-05-10 2014-10-31 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
WO2011154827A2 (en) 2010-06-11 2011-12-15 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
JP2013529595A (ja) 2010-06-11 2013-07-22 ローズ テクノロジーズ 第３級アミンのｎ−脱アルキル化方法
AU2011274361B2 (en) 2010-07-02 2014-09-18 Macfarlan Smith Limited Process for the synthesis and purification of oxycodone
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
US9414988B2 (en) 2011-09-05 2016-08-16 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
EP3078370B1 (en) 2011-09-16 2018-11-07 Purdue Pharma L.P. Tamper resistant immediate release formulations
MX355478B (es) 2011-09-16 2018-04-19 Purdue Pharma Lp Formulaciones farmacéuticas resistentes a la manipulación.
US20150265536A1 (en) 2011-12-09 2015-09-24 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
IN2014MN01901A (el) 2012-03-02 2015-07-10 Rhodes Pharmaceuticals Lp
KR102082529B1 (ko) 2012-04-17 2020-02-27 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
TR201815502T4 (tr) 2012-04-18 2018-11-21 Gruenenthal Gmbh Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
US10316042B2 (en) * 2012-07-16 2019-06-11 Rhodes Technologies Process for improved opioid synthesis
US20150259355A1 (en) 2012-07-16 2015-09-17 Rhodes Technologies Process for improved opioid synthesis
GB2519486A (en) * 2012-08-03 2015-04-22 Johnson Matthey Plc A method for preparing oxycodone
MX392839B (es) 2012-11-30 2025-03-24 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014130714A1 (en) * 2013-02-20 2014-08-28 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
US9120800B2 (en) 2013-08-02 2015-09-01 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone alkaloid and oxymorphone salts
MX2016005187A (es) 2013-11-07 2016-08-08 Mallinckrodt Llc Produccion de 6-hidroxi morfinanos sin el aislamiento de intermediarios.
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
CN106029669B (zh) 2014-01-15 2018-04-13 罗德科技公司 改进的羟二氢吗啡酮合成的方法
MX374394B (es) 2014-01-15 2025-03-06 Rhodes Tech Proceso para la sintesis mejorada de oxicodona.
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015145459A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
MA40332A (fr) * 2014-07-09 2021-04-28 Rhodes Tech Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) * 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20180104236A1 (en) 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10941154B2 (en) 2017-06-20 2021-03-09 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
US12201629B2 (en) 2017-06-30 2025-01-21 Purdue Pharma L.P. Method of treatment and dosage forms thereof
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US420098A (en) * 1890-01-28 Mowing-machine
DE296916C (el) *
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US1485673A (en) * 1924-03-04 Ministrator
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
DE286431C (el)
US1468805A (en) 1923-09-25 Htabtin ereund
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (el) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (el) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
KR930001499B1 (ko) * 1987-07-07 1993-03-02 오끼뎅끼 고오교오 가부시끼가이샤 반도체 장치의 제조방법
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
PT1014941E (pt) 1996-06-26 2009-07-08 Univ Texas Formulação farmacêutica extrudível por termofusão
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) * 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
WO2000021728A1 (en) * 1998-10-14 2000-04-20 Åmic AB A matrix and method of producing said matrix
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
AU776904B2 (en) * 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20030194748A1 (en) 2000-05-29 2003-10-16 Tohru Nagasaki Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
IL158882A0 (en) * 2001-06-05 2004-05-12 Control Delivery Sys Inc Sustained-release analgesic compounds
EP1392250A2 (en) 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
PT1416842E (pt) 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
ES2562682T3 (es) * 2002-01-15 2016-03-07 Novartis Ag Sistema para liberar aerosoles del espacio muerto anatómico efectivo
JP4790219B2 (ja) * 2002-03-26 2011-10-12 ユーロ−セルティーク エス．エイ． 徐放性ゲルコーティング組成物
PL373031A1 (en) * 2002-04-29 2005-08-08 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
EP1509050A4 (en) * 2002-05-27 2009-03-18 Ntt Docomo Inc MOBILE COMMUNICATION SYSTEM, TRANSMISSION STATION, RECEPTION STATION, RELAY STATION, METHOD FOR DECISION-MAKING THE COMMUNICATION PATH AND PROGRAM FOR DECISION-MAKING THE COMMUNICATION PATH
PL372797A1 (en) 2002-05-31 2005-08-08 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
CN100439373C (zh) * 2002-08-15 2008-12-03 诺拉姆科有限公司 羟考酮盐酸盐多晶型物
AU2003291103A1 (en) 2002-11-15 2004-06-15 Branded Products For The Future Pharmaceutical composition
AU2003293180A1 (en) * 2002-11-29 2004-06-23 Forest Laboratories Inc Combination of ibuprofen and oxycodone for acute pain relief
FR2850576B1 (fr) 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
WO2004082620A2 (en) 2003-03-13 2004-09-30 Controlled Chemicals, Inc. Oxycodone conjugates with lower the abuse potential and extended duration of action
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
WO2005098414A1 (en) * 2004-03-30 2005-10-20 Euro-Celtique S.A Methods for detecting 14-hydroxycodeinone and codeinone
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
JP5329083B2 (ja) 2004-06-25 2013-10-30 テッセラ，インコーポレイテッド ポストおよびパッドを有する部品
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
CA2598774C (en) 2005-03-04 2010-12-21 Euro-Celtique S.A. Method of reducing alpha, beta unsaturated ketones in opioid compositions
US8067597B2 (en) 2005-06-16 2011-11-29 Mallinckrodt Llc Synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs
MX2008006710A (es) 2005-11-22 2008-12-16 Controlled Chemicals Inc Procedimientos para reducir niveles de aceptor de michael contaminantes en oxicodona y otras composiciones.
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
AU2007224221B2 (en) 2006-03-02 2013-02-14 SpecGx LLC Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
JP2010511726A (ja) * 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド １４−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法
AU2007329451B2 (en) 2006-12-04 2012-08-30 Noramco, Llc Process for reducing impurities in oxycodone base
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
AU2011274361B2 (en) 2010-07-02 2014-09-18 Macfarlan Smith Limited Process for the synthesis and purification of oxycodone
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
KR20110110377A (ko) 2011-10-06
EP2305683A1 (en) 2011-04-06
JP2018184462A (ja) 2018-11-22
EP2305683B1 (en) 2015-01-28
EP2426132A1 (en) 2012-03-07
US20210094963A1 (en) 2021-04-01
PT2426132E (pt) 2016-03-31
US12060361B2 (en) 2024-08-13
CA2774121A1 (en) 2005-10-20
EP2426132B1 (en) 2016-01-13
CY1116327T1 (el) 2017-02-08
PL1730151T5 (pl) 2023-09-18
US20090227615A1 (en) 2009-09-10
CN101812065A (zh) 2010-08-25
DK1730151T4 (da) 2020-10-19
EA013208B1 (ru) 2010-04-30
ES2938727T3 (es) 2023-04-14
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
CA2557845A1 (en) 2005-10-20
US20200087316A1 (en) 2020-03-19
KR20200000499A (ko) 2020-01-02
US20070117829A1 (en) 2007-05-24
US10689389B2 (en) 2020-06-23
ES2535618T3 (es) 2015-05-13
CR20110376A (es) 2011-09-19
HRP20180407T1 (hr) 2018-04-20
HRP20110425T4 (hr) 2020-11-27
JP5543991B2 (ja) 2014-07-09
HK1155729A1 (en) 2012-05-25
CN102838607B (zh) 2016-08-03
EP1730151A4 (en) 2007-05-23
RS51693B (sr) 2011-10-31
IL214050A0 (en) 2011-08-31
MA28492B1 (fr) 2007-03-01
US20180022754A1 (en) 2018-01-25
AR049012A1 (es) 2006-06-21
JP5118223B2 (ja) 2013-01-16
DE602005026786D1 (de) 2011-04-21
IL213888A0 (en) 2011-07-31
US20160250204A1 (en) 2016-09-01
IL178038A0 (en) 2006-12-31
KR20120106784A (ko) 2012-09-26
EP1730151B1 (en) 2011-03-09
DK2426132T3 (en) 2016-04-04
CA2557845C (en) 2013-10-01
US10696684B2 (en) 2020-06-30
RS57000B1 (sr) 2018-05-31
HRP20150358T1 (hr) 2015-05-08
JP2011157370A (ja) 2011-08-18
EP2311839A1 (en) 2011-04-20
SG10201406658VA (en) 2014-12-30
US8822687B2 (en) 2014-09-02
KR20140021716A (ko) 2014-02-20
MY143205A (en) 2011-03-31
US20160185790A1 (en) 2016-06-30
TWI483944B (zh) 2015-05-11
US20160251364A1 (en) 2016-09-01
SI2316837T1 (en) 2018-05-31
ES2665287T3 (es) 2018-04-25
JP2014139205A (ja) 2014-07-31
US20160175298A1 (en) 2016-06-23
SI1730151T2 (sl) 2021-03-31
NO337669B1 (no) 2016-05-30
KR20100069719A (ko) 2010-06-24
DK1730151T3 (da) 2011-06-20
MY172063A (en) 2019-11-13
US20160185788A1 (en) 2016-06-30
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
US11384091B2 (en) 2022-07-12
EP1730151B2 (en) 2020-09-16
PT2319846T (pt) 2016-08-12
US9777011B2 (en) 2017-10-03
MX2020008878A (es) 2020-11-09
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
ES2362282T3 (es) 2011-06-30
US20130005977A1 (en) 2013-01-03
US20160176888A1 (en) 2016-06-23
SG170735A1 (en) 2011-05-30
BRPI0508758B1 (pt) 2018-10-09
AU2009200335A1 (en) 2009-02-26
US20070179169A1 (en) 2007-08-02
US7129248B2 (en) 2006-10-31
SI1730151T1 (sl) 2011-06-30
ME02482B (me) 2017-02-20
RS54598B1 (sr) 2016-08-31
BRPI0508758A (pt) 2007-08-28
PE20050880A1 (es) 2005-11-16
DK2319846T3 (en) 2016-08-15
JP6503392B2 (ja) 2019-04-17
IL213891A0 (en) 2011-07-31
AU2009200335B2 (en) 2011-07-28
US20160175299A1 (en) 2016-06-23
RS53891B1 (sr) 2015-08-31
JP2015187134A (ja) 2015-10-29
IL213890A (en) 2015-10-29
US9522919B2 (en) 2016-12-20
AU2005230826C1 (en) 2014-10-16
LT2316837T (lt) 2018-04-10
CN102887903A (zh) 2013-01-23
US20190161492A1 (en) 2019-05-30
PL2319846T3 (pl) 2016-12-30
EA200601520A1 (ru) 2007-02-27
SG170736A1 (en) 2011-05-30
US10259819B2 (en) 2019-04-16
EP2319846A1 (en) 2011-05-11
DK2316837T3 (en) 2018-04-16
SI2426132T1 (sl) 2016-04-29
US20160185789A1 (en) 2016-06-30
TW201509943A (zh) 2015-03-16
US7674798B2 (en) 2010-03-09
EP2316837A1 (en) 2011-05-04
ATE501150T1 (de) 2011-03-15
NZ549430A (en) 2010-05-28
US20230365578A1 (en) 2023-11-16
HUE036451T2 (hu) 2018-07-30
JP2007531756A (ja) 2007-11-08
ME02411B (me) 2016-09-20
JP4912294B2 (ja) 2012-04-11
IL213889A0 (en) 2011-07-31
IL213889A (en) 2012-06-28
EP2305683B8 (en) 2015-03-04
AP2006003738A0 (en) 2006-10-31
NZ601326A (en) 2013-10-25
US20060173029A1 (en) 2006-08-03
MX363228B (es) 2019-03-15
HUE029913T2 (en) 2017-04-28
AU2005230826A1 (en) 2005-10-20
TW201231469A (en) 2012-08-01
PT2316837T (pt) 2018-04-02
BRPI0508758B8 (pt) 2021-05-25
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
NO20064935L (no) 2006-12-18
DE202005021371U1 (de) 2007-10-25
CA2913355A1 (en) 2005-10-20
CN1960994A (zh) 2007-05-09
IL241117A0 (en) 2015-11-30
SI2319846T1 (sl) 2016-08-31
ES2566363T3 (es) 2016-04-12
KR101410141B1 (ko) 2014-06-25
CN102838607A (zh) 2012-12-26
CY1120171T1 (el) 2018-12-12
US10407434B2 (en) 2019-09-10
PT2305683E (pt) 2015-05-18
KR20120046309A (ko) 2012-05-09
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
IL178038A (en) 2015-10-29
DK200700214U1 (da) 2007-11-23
US7674799B2 (en) 2010-03-09
RS54941B1 (sr) 2016-11-30
CN101812065B (zh) 2012-03-28
TWI365880B (en) 2012-06-11
ECSP066953A (es) 2006-12-20
HK1155728A1 (en) 2012-05-25
EP2316837B1 (en) 2018-01-10
DK200700214U3 (da) 2008-02-08
KR20070022033A (ko) 2007-02-23
HRP20160223T1 (hr) 2016-03-25
FI7843U1 (fi) 2008-04-28
JP5378486B2 (ja) 2013-12-25
US9073933B2 (en) 2015-07-07
JP2017125052A (ja) 2017-07-20
US20210198268A1 (en) 2021-07-01
IL213890A0 (en) 2011-07-31
PT1730151E (pt) 2011-06-01
SI2305683T1 (sl) 2015-04-30
RS51693B2 (sr) 2021-02-26
IL235298A (en) 2016-11-30
ES2585576T3 (es) 2016-10-06
EP2314589A1 (en) 2011-04-27
HRP20110425T1 (en) 2011-07-31
US20160251365A1 (en) 2016-09-01
EP1730151A1 (en) 2006-12-13
EP2305683B2 (en) 2024-09-11
JP2012072162A (ja) 2012-04-12
HUE028233T2 (en) 2016-12-28
CN102127086A (zh) 2011-07-20
PL2316837T3 (pl) 2018-07-31
CN1960994B (zh) 2012-09-05
PL1730151T3 (pl) 2011-08-31
DK2305683T3 (en) 2015-04-07
PL2426132T3 (pl) 2016-06-30
IL241117B (en) 2020-06-30
LT2314589T (lt) 2023-06-12
US20050222188A1 (en) 2005-10-06
ME01299B (me) 2011-10-31
US20150265597A1 (en) 2015-09-24
CA2774121C (en) 2016-02-16
KR20140133615A (ko) 2014-11-19
EP2314589B1 (en) 2022-12-28
JP2012188439A (ja) 2012-10-04
US20200062772A1 (en) 2020-02-27
US20150265598A1 (en) 2015-09-24
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
ME03068B (me) 2019-01-20
US20160251363A1 (en) 2016-09-01
US20160264588A1 (en) 2016-09-15
US20150258086A1 (en) 2015-09-17
ES2362282T5 (es) 2021-06-24
WO2005097801A1 (en) 2005-10-20
CY1111487T1 (el) 2015-08-05
AT9952U1 (de) 2008-06-15
MY154985A (en) 2015-08-28
US20160176889A1 (en) 2016-06-23
US20070117831A1 (en) 2007-05-24
CA2913355C (en) 2021-04-20
KR20130020962A (ko) 2013-03-04
CY1117228T1 (el) 2017-04-05
US7674800B2 (en) 2010-03-09
KR20180088505A (ko) 2018-08-03
KR101200700B1 (ko) 2012-11-13
EP2319846B1 (en) 2016-05-04
US20230159548A1 (en) 2023-05-25
KR20090104145A (ko) 2009-10-05
IL214050A (en) 2013-09-30
HK1098745A1 (en) 2007-07-27
FIU20070284U0 (fi) 2007-07-04
ZA200607181B (en) 2007-11-28
US20100152449A1 (en) 2010-06-17
CN102887903B (zh) 2016-01-27
HRP20160885T1 (hr) 2016-09-23
CR8593A (es) 2007-07-19
AU2005230826B2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
CY1120171T1 (el) Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
TWI369429B (en) Additive compositions for treating various base sheets
ATE435271T1 (de) Zusammensetzungen zur wäschebehandlung
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
TW200639161A (en) Process for the purification of duloxetine hydrochloride
DE602005006185D1 (de) Entwicklungsverfahren
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
EP1765735A4 (en) SLUDGE TREATMENT PROCESS
EA200800324A1 (ru) Новый способ получения солей тиотропия
DE602004004284D1 (de) Datum-korrigierer
DE602005008721D1 (de) Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid
EA200700654A1 (ru) Способ очистки глины
GEP20094655B (en) Process for preparing oxycodone hydrochloride having less than 25 pm 14-hydroxycodeinone
DE602006018503D1 (de) Verfahren zur herstellung von 1-benzyl-4-ä(5,6-dimethoxy-1indanon)-2-ylümethylpiperidin oder des hydrochlorids davon
ATE482198T1 (de) Sitamaquintosylat zur behandlung von leishmaniase
PL379108A1 (pl) Sacharyniany 1-alkoksymetylo-3-dimetyloaminopirydyniowe i sacharyniany 1-alkoksymetylo-4-dimetyloaminopirydyniowe oraz sposób wytwarzania sacharynianów 1-alkoksymetylo-3-dimetyloaminopirydyniowych i sacharynianów 1-alkoksymetylo-4-dimetyloaminopirydyniowych
ATE489366T1 (de) Verfahren zur herstellung von 1-benzyl-4-ä(5,6- dimethoxy-1indanon)-2-ylümethylpiperidin oder des hydrochlorids davon
ITRC20050003A1 (it) "copia"
FI20041225L (fi) Tuhkan esikäsittelymenetelmä
SE0400584D0 (sv) NNRTI Antivirals II
FI20041315A0 (fi) Prosessi
ATE458804T1 (de) Zusammensetzungen zur wäschebehandlung
UA7908S (uk) Комплект панелей грального автомата «jokers plus»
SE0400123D0 (sv) Självsläckande ljus
DE60335299D1 (de) Verbrennungsverfahren